MedPath

UNIVERSITY OF ALABAMA AT BIRMINGHAM

πŸ‡ΊπŸ‡ΈUnited States
Ownership
-
Established
1969-01-01
Employees
2K
Market Cap
-
Website
http://www.uab.edu

Return of Aspiration-Free Swallow After Laryngotracheal Anesthesia

Completed
Conditions
Swallowing, Air
Interventions
Other: waiting period
First Posted Date
2020-10-05
Last Posted Date
2024-04-24
Lead Sponsor
University of Alabama at Birmingham
Target Recruit Count
30
Registration Number
NCT04575870
Locations
πŸ‡ΊπŸ‡Έ

University of Alabama at Birmingham, Birmingham, Alabama, United States

Nutritive Sucking Patterns in Premature Infants

Not Applicable
Withdrawn
Conditions
Premature
Light-For-Dates Without Mention of Fetal Malnutrition, Unspecified
Feeding Patterns
Interventions
Diagnostic Test: Control
Diagnostic Test: Reporting of sucking patterns captured by Instrumented Bottle
First Posted Date
2020-09-24
Last Posted Date
2022-01-10
Lead Sponsor
University of Alabama at Birmingham
Registration Number
NCT04561700

Antiviral Effects of TXA as a Preventative Treatment Following COVID-19 Exposure

Phase 3
Withdrawn
Conditions
COVID-19
Interventions
First Posted Date
2020-09-16
Last Posted Date
2021-04-23
Lead Sponsor
University of Alabama at Birmingham
Registration Number
NCT04550338

Gait Training Combined With Behavioral Strategies for People With Stroke

Not Applicable
Completed
Conditions
Gait, Hemiplegic
Behavior and Behavior Mechanisms
Stroke
Interventions
Device: Treadmill training (TT)
Combination Product: Treadmill training + transfer package (TT+TP)
First Posted Date
2020-09-11
Last Posted Date
2024-05-22
Lead Sponsor
University of Alabama at Birmingham
Target Recruit Count
19
Registration Number
NCT04546217
Locations
πŸ‡ΊπŸ‡Έ

University of Alabama at Birmingham, Birmingham, Alabama, United States

A Phase II Trial of Poly-ICLC for Low-Grade Gliomas

Phase 2
Recruiting
Conditions
NF1
Low-grade Glioma
Interventions
First Posted Date
2020-09-10
Last Posted Date
2024-03-15
Lead Sponsor
University of Alabama at Birmingham
Target Recruit Count
20
Registration Number
NCT04544007
Locations
πŸ‡ΊπŸ‡Έ

Children's Healthcare of Atlanta, Atlanta, Georgia, United States

πŸ‡ΊπŸ‡Έ

The University of Alabama at Birmingham (Site 700), Birmingham, Alabama, United States

πŸ‡ΊπŸ‡Έ

Children's Lurie Hospital, Chicago, Illinois, United States

and more 9 locations

Neuroinflammation and Age-associated Brain Pathology: Two Potential Mechanisms of Cognitive Impairment in Ovarian Cancer

Phase 1
Withdrawn
Conditions
Ovarian Cancer
Interventions
Drug: [11C]PiB and 18F-labeled DPA-714 PET scan
First Posted Date
2020-09-09
Last Posted Date
2024-04-25
Lead Sponsor
University of Alabama at Birmingham
Registration Number
NCT04542603

Glycemic Control After Antenatal Corticosteroids in Women with Pregestational and Gestational Diabetes

Phase 2
Recruiting
Conditions
Diabetes Mellitus, Type 2
Preterm Birth
Pregnancy, High Risk
Diabetes, Gestational
Interventions
Drug: Up-Titration of Home Insulin
Drug: Continuous Insulin Infusion
Drug: Sliding Scale Insulin
Device: Dexcom G6 Professional Continuous Glucose Monitor
First Posted Date
2020-09-09
Last Posted Date
2024-10-08
Lead Sponsor
University of Alabama at Birmingham
Target Recruit Count
120
Registration Number
NCT04542148
Locations
πŸ‡ΊπŸ‡Έ

University of Alabama at Birmingham, Birmingham, Alabama, United States

πŸ‡ΊπŸ‡Έ

Oregon Health and Science University, Portland, Oregon, United States

πŸ‡ΊπŸ‡Έ

University of South Carolina Greenville / Prisma Health-Upstate, Greenville, South Carolina, United States

and more 1 locations

COVID-19 Study of Safety and Tolerability of Alvelestat

Phase 1
Completed
Conditions
Covid19
Interventions
Drug: Placebo
Drug: Alvelestat
First Posted Date
2020-09-07
Last Posted Date
2023-01-19
Lead Sponsor
University of Alabama at Birmingham
Target Recruit Count
15
Registration Number
NCT04539795
Locations
πŸ‡ΊπŸ‡Έ

UAB Lung Health Center, Birmingham, Alabama, United States

Postpartum Glycemia in Women At Risk for Persistent Hyperglycemia

Not Applicable
Completed
Conditions
Gestational Diabetes
Interventions
Diagnostic Test: 2-hour 75-g oral glucose tolerance test and Dexcom G6 Pro continuous glucose monitor
First Posted Date
2020-08-20
Last Posted Date
2024-12-18
Lead Sponsor
University of Alabama at Birmingham
Target Recruit Count
40
Registration Number
NCT04521712
Locations
πŸ‡ΊπŸ‡Έ

University of Alabama at Birmingham, Birmingham, Alabama, United States

πŸ‡ΊπŸ‡Έ

University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States

Phase II Panitumumab-IRDye800 in Head & Neck Cancer

Phase 2
Recruiting
Conditions
Head and Neck Cancer
Interventions
Drug: Panitumumab-IRDye800
First Posted Date
2020-08-12
Last Posted Date
2024-04-03
Lead Sponsor
University of Alabama at Birmingham
Target Recruit Count
25
Registration Number
NCT04511078
Locations
πŸ‡ΊπŸ‡Έ

University of Alabama at Birmingham, Birmingham, Alabama, United States

Β© Copyright 2025. All Rights Reserved by MedPath